Learn about support and programs that may help you pay for GILOTRIF.

Get resources to help you

 
Take advantage of the resources that may be available to you while taking GILOTRIF.

Biomarker testing is an important part of NSCLC diagnosis

If you’ve been diagnosed with non-small cell lung cancer (NSCLC) that has spread to other parts of your body (referred to as metastatic), your doctor may order a special test to see if your tumors have a specific kind of epidermal growth factor receptor (EGFR) mutation (EGFR M+).

The test can have different names, but it’s often called a biomarker test. Doctors take a sample (called a biopsy) of the tumor to learn more about the cancer. Mutated EGFR is a target molecule involved in tumor growth, and testing for the EGFR mutation is an important step in deciding appropriate treatment.

A mutation that can cause signals to go awry

Epidermal growth factor receptor (EGFR) is a molecule that sits on the surface of healthy cells, including lung cells, transmitting signals that tell the cell what to do—for example, whether or not it should grow. A mutation, or defect, in the molecule can cause it to transmit too many signals, which may make the cell grow out of control.

There are different processes that can cause a cell to become cancerous. The results of the biomarker tests can help doctors to identify what is causing the problem, as this information can help determine a treatment plan. This is generally accomplished by testing a sample of the tumor.

Patients with untreated, advanced (metastatic), non-small cell lung cancers (NSCLCs) that test positive for certain EGFR mutations may be eligible to be treated with GILOTRIF.

WHAT IS GILOTRIF?

GILOTRIF is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC) that:

• has certain (non-resistant) abnormal epidermal growth factor receptor (EGFR) gene(s). Your healthcare provider will perform a test to make sure that GILOTRIF is right for you.

• has spread to other parts of the body (metastatic), and

• has not been previously treated for metastatic lung cancer

It is not known if GILOTRIF is safe and effective in treating people with lung cancer that has resistant abnormal EGFR genes.

or

is used to treat people with squamous cell lung cancer that:

• has spread to other parts of the body, and

• has been previously treated with chemotherapy that contains platinum.


It is not known if GILOTRIF is safe and effective in children.